AKT1 and glioblastoma: PRMT2 inactivation has been shown to inhibit GBM cell growth and enhance TMZ sensitivity in mouse models, causing significant dysregulation of genes involved in cell cycle progression and oncogenic pathways such as PI3 K/AKT, MAPK, JAK/STAT, and Wnt/β-catenin [200].